SHANGHAI GROWTH (00770): Li Canhua appointed as independent non-executive director.
SHANGHAI GROWTH (00770) announced that Mr. Li Canhua has been appointed as an independent non-executive director, chairman of the Audit Committee, and member of the Remuneration Committee with effect from January 30, 2026; Ms. Zhang Yuefen has resigned from the positions of Company Secretary, Authorized Representative, and agent for accepting legal process documents; Ms. Liu Meixue has resigned as an independent non-executive director and no longer serves as chairman of the Audit Committee and Nomination Committee, as well as a member of the Remuneration Committee, and has been appointed as Company Secretary, Authorized Representative, and agent for accepting legal process documents; Ms. Shi Meiling has been appointed as chairman of the Nomination Committee.
Shanghai Growth (00770) announced that as of January 30, 2026, Mr. Li Canhua has been appointed as an independent non-executive director, chairman of the audit committee, and member of the remuneration committee; Ms. Zhang Yuefen has resigned from the positions of company secretary, authorized representative, and agent for accepting legal process documents; Ms. Liu Meixue has resigned as an independent non-executive director, and no longer serves as chairman of the audit committee and nomination committee, as well as a member of the remuneration committee, and has been appointed as company secretary, authorized representative, and agent for accepting legal process documents; Ms. Shi Meiling has been appointed as chairman of the nomination committee.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


